BackCharles River Laboratories International Overview
Charles River Laboratories International Inc.

Charles River Laboratories International Target Price

Analysts' average 12-month price target for Charles River Laboratories International is $270.

Get informed when a big investor buys or sells

+ Follow

Share Price

$292.84

Average Target Price

$272.576.9% downside

14 analysts in the last 4 months

High: $330 | Low: $219

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-17Argus Research$33012.7% upsideOpen
2026-09-11Evercore ISI$3209.3% upsideOpen
2026-08-10Piper Sandler$3002.4% upsideOpen
2026-08-10Mizuho Securities$2649.8% downsideOpen
2026-08-07Morgan Stanley$3002.4% upsideOpen
2026-08-06Robert W. Baird$2910.6% downsideOpen
2026-08-06RBC Capital$2823.7% downsideOpen
2026-08-05Barclays$3002.4% upsideOpen
2026-07-13Mizuho Securities$23021.5% downsideOpen
2026-07-09Morgan Stanley$26011.2% downsideOpen
2026-07-01Bernstein$25014.6% downsideOpen
2026-07-01BNP Paribas$25014.6% downsideOpen
2026-06-17Morgan Stanley$22024.9% downsideOpen
2026-05-29CLSA$21925.2% downsideOpen
2026-05-08Robert W. BairdEric Coldwell$21327.3% downsideOpen
2026-05-08Evercore ISI$22024.9% downsideOpen
2026-05-08Mizuho Securities$19234.4% downsideOpen
2026-05-08BarclaysLuke Sergott$22024.9% downsideOpen
2026-04-14BarclaysLuke Sergott$21028.3% downsideOpen
2026-04-14RBC Capital$21526.6% downsideOpen
2026-02-20Mizuho Securities$17540.2% downsideOpen
2026-02-19Robert W. BairdEric Coldwell$19334.1% downsideOpen
2026-02-19BarclaysLuke Sergott$20031.7% downsideOpen
2026-01-13Robert W. Baird$23121.1% downsideOpen
2026-01-13Evercore ISI$26011.2% downsideOpen
2026-01-09Robert W. BairdEric Coldwell$22423.5% downsideOpen
2026-01-09Mizuho SecuritiesAnn Hynes$21526.6% downsideOpen
2025-12-18Mizuho Securities$20031.7% downsideOpen
2025-12-15Barclays$21526.6% downsideOpen
2025-12-01Morgan StanleyKallum Titchmarsh$18536.8% downsideOpen
2025-11-17Argus Research$20031.7% downsideOpen
2025-10-17Mizuho SecuritiesAnn Hynes$17440.6% downsideOpen
2025-10-03Evercore ISIElizabeth Anderson$20031.7% downsideOpen
2025-10-02BarclaysLuke Sergott$19533.4% downsideOpen
2025-09-09Jefferies$19533.4% downsideOpen
2024-10-15BarclaysLuke Sergott$20530% downsideOpen
2024-10-14Redburn PartnersJamie Clark$15148.4% downsideOpen
2024-09-17Mizuho SecuritiesAnn Hynes$21028.3% downsideOpen
2024-08-08Deutsche BankJustin Bowers$24018% downsideOpen
2024-07-10Robert W. BairdEric Coldwell$23918.4% downsideOpen
2024-06-28BarclaysLuke Sergott$23021.5% downsideOpen
2024-06-06Goldman SachsMatthew Sykes$2901% downsideOpen
2024-05-09Evercore ISIElizabeth Anderson$2659.5% downsideOpen
2024-04-01Evercore ISIElizabeth Anderson$3002.4% upsideOpen
2022-05-05KeyBancDonald Hooker$3002.4% upsideOpen
2022-04-25Wells Fargo$32511% upsideOpen
2022-04-25JefferiesDavid Windley$2804.4% downsideOpen
2022-01-11JefferiesDavid Windley$46458.4% upsideOpen
2021-11-24Argus ResearchDavid Toung$44050.3% upsideOpen
2021-08-17Cowen & Co.Daniel Brennan$46558.8% upsideOpen

Charles River Laboratories International (CRL) FAQ

Charles River Laboratories International posts a target price of $270. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $270 for CRL means covering analysts, on average, see the stock 6.9% downside of $292.84 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CRL's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Charles River Laboratories International's other metric pages and overview cover the third.

Judging Charles River Laboratories International against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $270 here, then scan peer and history charts to see if the gap is persistent.